STUDIES IN HEALTH SCIENCES,
Год журнала:
2024,
Номер
5(4), С. e11497 - e11497
Опубликована: Дек. 4, 2024
A
obesidade
é
uma
doença
crônica
caracterizada
pelo
depósito
excessivo
de
gordura,
impactando
na
qualidade
vida
e
favorecendo
o
desenvolvimento
diversas
outras
patologias
associadas.
O
presente
estudo
tem
por
objetivo
analisar
quais
as
consequências
clínicas
do
uso
Ozempic
no
combate
à
obesidade.
Trata-se
pesquisa
revisão
integrativa
da
literatura
com
dos
termos
“Weight
Loss”,
“Drug-Related
Side
Effects
and
Adverse
Reactions”,
“Semaglutide”
associados
ao
operador
booleano
“AND”
a
ser
realizado
nas
bases
dados
Biblioteca
Virtual
em
Saúde
(BVS)
National
Library
of
Medicine
(PUBMED).
Foram
encontrados
8
artigos
BVS
PUBMED.
Após
aplicação
filtros,
foram
analisados
3
cada
das
respectivas
plataformas.
Concluiu-se
que
semaglutida
está
associado
aos
efeitos
colaterais
diversos
sistemas.
maioria
pouca
repercussão.
Seu
considerado
seguro,
não
livre
adversos,
sendo
necessário
riscos
benefícios.
Early Intervention in Psychiatry,
Год журнала:
2025,
Номер
19(4)
Опубликована: Апрель 1, 2025
ABSTRACT
Background
Prior
research
has
shown
varying
suicide
attempt
rates
based
on
the
age
of
onset
in
major
depressive
disorder
(MDD)
patients.
However,
there
is
a
paucity
psychotic
(PMD)
This
study
aimed
to
assess
prevalence
and
correlates
attempts
PMD
patients
stratified
by
onset.
Methods
Totally,
1718
first‐episode
drug‐naïve
MDD
outpatients
were
recruited,
divided
into
early‐age
(EAO)
middle‐age
(MAO)
first
episode
before
45/after
45.
Clinical
severity
was
assessed
using
Hamilton
Depression
Rating
Scale
(HAMD),
Anxiety
(HAMA)
Positive
Negative
Syndrome
(PANSS)
positive
subscale.
In
addition,
thyroid
hormone
glucolipid
metabolism
indicators
measured.
Results
EAO
patients,
HAMA
scale
score
thyroid‐stimulating
(TSH)
levels
associated
with
attempts.
The
area
under
receiver
operating
characteristic
curve
(AUROC)
0.892.
MAO
TSH
diastolic
blood
pressure
AUROC
0.862.
Conclusion
demonstrates
that
vary
among
different
ages
Age
should
be
considered
prevention
treatment
PMD.
Journal of Medical Toxicology,
Год журнала:
2024,
Номер
20(3), С. 278 - 285
Опубликована: Июнь 11, 2024
Glucagon-like
peptide-1
receptor
agonist
use
has
increased
over
the
last
decade
for
glycemic
control
in
type
2
diabetes
mellitus,
cardiovascular
risk
reduction,
and
weight
loss.
Clinical
trials
indicate
that
gastrointestinal
adverse
effects
are
commonly
experienced
severe
hypoglycemia
is
rare;
however,
there
little
data
regarding
glucagon-like
overdose.
Arhiv za farmaciju,
Год журнала:
2024,
Номер
74(3), С. 460 - 482
Опубликована: Янв. 1, 2024
Obesity
is
a
chronic,
progressive,
and
recurring
disease.
The
prevalence
of
obesity
has
reached
pandemic
proportions,
along
with
overweight-related
conditions
like
diabetes,
cardiovascular
diseases,
certain
cancers.
Reducing
residual
morbidity
the
main
goal
treatment.
Pharmacotherapy
intended
for
patients
who
have
not
responded
to
lifestyle
interventions.
There
are
currently
six
anti-obesity
medications
(orlistat,
phentermine/topiramate,
naltrexone/bupropion,
liraglutide,
semaglutide,
tirzepatide)
approved
long-term
management.
Most
them,
except
orlistat,
predominantly
act
centrally
by
increasing
satiety,
as
well
reducing
appetite
food
reward.
most
effective
drugs
semaglutide
tirzepatide,
which
might
provide
weight
loss
more
than
10%
initial
weight.
Although
all
been
demonstrated
improve
cardiometabolic
risk
factors,
only
liraglutide
lower
major
events
in
or
without
established
A
personalized
approach,
considering
both
drug
(weight-reducing
capacity
safety)
patient
(comorbidities,
age,
patient's
preferences)
features,
guarantees
best
results.
In
this
article,
we
will
critically
appraise
efficacy
safety
those
pipeline.
STUDIES IN HEALTH SCIENCES,
Год журнала:
2024,
Номер
5(4), С. e11497 - e11497
Опубликована: Дек. 4, 2024
A
obesidade
é
uma
doença
crônica
caracterizada
pelo
depósito
excessivo
de
gordura,
impactando
na
qualidade
vida
e
favorecendo
o
desenvolvimento
diversas
outras
patologias
associadas.
O
presente
estudo
tem
por
objetivo
analisar
quais
as
consequências
clínicas
do
uso
Ozempic
no
combate
à
obesidade.
Trata-se
pesquisa
revisão
integrativa
da
literatura
com
dos
termos
“Weight
Loss”,
“Drug-Related
Side
Effects
and
Adverse
Reactions”,
“Semaglutide”
associados
ao
operador
booleano
“AND”
a
ser
realizado
nas
bases
dados
Biblioteca
Virtual
em
Saúde
(BVS)
National
Library
of
Medicine
(PUBMED).
Foram
encontrados
8
artigos
BVS
PUBMED.
Após
aplicação
filtros,
foram
analisados
3
cada
das
respectivas
plataformas.
Concluiu-se
que
semaglutida
está
associado
aos
efeitos
colaterais
diversos
sistemas.
maioria
pouca
repercussão.
Seu
considerado
seguro,
não
livre
adversos,
sendo
necessário
riscos
benefícios.
